HSD17B13 and metabolic dysfunction-associated steatotic liver disease: In humans, however, only people carrying certain mutations in hepatic genes (PNPLA3, PYGO1, TM6SF2, and HSD17B13) will develop NAFLD, as these mutations disrupt TG mobilisation and secretion, leading to fat accumulation28.